These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23718846)

  • 1. Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
    Mangiacavalli S; Pochintesta L; Cocito F; Pompa A; Bernasconi P; Cazzola M; Corso A
    Br J Haematol; 2013 Aug; 162(4):555-8. PubMed ID: 23718846
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Avvisati G
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Islam A; Ambrus JL
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
    Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
    Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
    Moreau P; Hulin C; Facon T
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):829-38. PubMed ID: 25212885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

  • 8. Frontline regimens for multiple myeloma patients.
    Lonial S
    Clin Adv Hematol Oncol; 2010 May; 8(5):331-2. PubMed ID: 20551891
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatic extramedullary disease in multiple myeloma with 17p deletion.
    Ise M; Tsujimura H; Sakai C; Kumagai K
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e165-8. PubMed ID: 25018063
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
    J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
    Tsurumi H
    Rinsho Ketsueki; 2014 Oct; 55(10):2027-35. PubMed ID: 25297768
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on recent developments for patients with newly diagnosed multiple myeloma.
    Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
    Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of elderly multiple myeloma patients.
    Palumbo A
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):529-30. PubMed ID: 20966887
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimising bortezomib in newly diagnosed multiple myeloma.
    Rajkumar SV
    Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of myeloma--are we making progress?
    Durie BG
    N Engl J Med; 2008 Aug; 359(9):964-6. PubMed ID: 18753654
    [No Abstract]   [Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 19. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
    Minarik J; Sandecka V; Maisnar V; Gregora E; Spicka I; Starostka D; Plonkova H; Jarkovsky J; Walterova L; Wrobel M; Adamova D; Pika T; Melicharova H; Pour L; Radocha J; Pavlicek P; Straub J; Gumulec J; Bacovsky J; Adam Z; Scudla V; Hajek R
    Leuk Res; 2013 Sep; 37(9):1063-9. PubMed ID: 23845888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
    Gozzetti A; Musto P; Defina M; D'Auria F; Papini G; Statuto T; D'Arena G; Bocchia M
    Br J Haematol; 2012 May; 157(4):497-8. PubMed ID: 22296516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.